Read Our Investor Brief on Halozyme Therapeutics

Shares of Health Care sector company Halozyme Therapeutics moved 1.5% today, and are now trading at a price of $40.05. The mid-cap stock's daily volume was 413,235 compared to its average volume of 869,474. The S&P 500 index returned a -0.0% performance.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is based in San Diego and has 393 full time employees. Its market capitalization is $5,643,749,376.

11 analysts are following Halozyme Therapeutics and have set target prices ranging from $28.0 to $72.0 per share. On average, they have given the company a rating of buy. At today's prices, HALO is trading -21.87% away from its average analyst target price of $51.27 per share.

Over the last year, HALO shares have gone down by -30.6%, which represents a difference of -53.1% when compared to the S&P 500. The stock's 52 week high is $58.65 per share and its 52 week low is $29.85. With average free cash flows of $132.71 Million that have been growing at an average rate of 38.5% over the last 6 years, Halozyme Therapeutics declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 368,670 15,042 353,628 50.29
2022 240,110 4,810 235,300 -21.04
2021 299,440 1,457 297,983 462.76
2020 55,454 2,504 52,950 159.19
2019 -85,423 4,040 -89,463 -65.17
2018 -49,500 4,663 -54,163
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.